MILPITAS, Calif. - Aug. 21, 2020 -Coronaviruses are large, lipid-enveloped, single-stranded RNA viruses known to infect a wide array of hosts, including humans, bats, mice and other mammals. Amongst the seven known human coronaviruses, MERS-CoV, SARS-CoV-1 and SARS-CoV-2 are the most pathogenic, causing severe, potentially fatal respiratory and cardiovascular symptoms. SARS-CoV-2 has the transmembrane Spike protein is a glycoprotein responsible for host-cell binding and viral entry. It is a heterotrimeric complex with two unique subunits. The S1 subunit contains the Receptor Binding Domain (RBD), which interacts with Angiotensin-Converting Enzyme 2 (ACE2) as a host-cell receptor, whereas the S2 subunit mediates viral membrane fusion. The S protein is highly immunogenic, with seroconversion in infected individuals typically detected between 5-21 days following the onset of symptoms. BioVision's SARS-CoV-2 IgG ELISA Kit is an enzyme-linked immunosorbent assay intended for identifying the immune response to SARS-CoV-2 infection. The assay uses the spike protein S1 subunit as bait to capture anti-SARSCoV-2 antibodies in diluted plasma or serum samples. Subsequent reaction with an enzyme-labeled anti-human-IgG conjugate and a colorimetric substrate generates color, which is proportional to the amount of anti-S1 antibodies. The presence of anti-SARS-CoV-2 S1 antibodies (IgG) is determined by comparing the OD450 nm reading of the sample to the OD450 nm reading of the negative control serum. A positive reaction suggests prior SARS-CoV-2 infection that began ≥14 days ago. Positive control serum containing a recombinant human monoclonal anti-SARS-CoV-2 S1 antibody is included in the kit for validation. The assay is a quick, easy and accurate method of indicating recent or prior SARS-CoV-2 infection that does not require collection or handling of infectious virus.This kit is a valuable tool to study the COVID-19 epidemiology, prevalence & morbidity.

Figures: (a) Detection of Anti-SARS-CoV-2 IgG antibodies in serum samples. COVID-19 patient serum samples were obtained from individuals that had a positive test for SARS-CoV-2 viral RNA by RT-PCR from nasopharyngeal swab specimen. Healthy serum was donor-pooled off-the-clot serum obtained from healthy individuals prior to the COVID-19 pandemic. The response from Negative Control Serum was used to determine the cutoff for positivity . (b) Serial Dilutions of COVID-19 patient sera versus healthy serum.

For more information on this kit, visit: https://www.biovision.com/sars-cov-2-igg-elisa-kit.html

Media Contact
Marketing BioVision